© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 161 Farringdon Rd, London EC1R 3AL. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions | Cookies

SRI

Top section

Top section

SSA

Eurofima, BNG and NZ agency bring life back to SSA market

BNG deal 'most exciting' while Eurofima will test long-dated demand
Six tranche loan attracts record demand

ABN Amro returns to euro market with 'defensive' EuGB senior note

◆ Defensive structure for nervous market ◆ Largest book on a busy day for FIG issuance ◆ ABN keeps position of leading FIG EuGB issuer

Can I ever escape the pull of the business?

I don’t need to work, but I’m tempted to go back
Six tranche loan attracts record demand
Sub-sections
  • In mid-May GlobalCapital convened representatives of three RMBS issuers with different business models and approaches for a wide-ranging discussion about the state of the UK mortgage markets, funding strategies, and much more. Kensington is the most frequent issuer in European RMBS, with a track record stretching back to 1995, and more than £10bn of assets under management, including about £6bn of servicing mandates. LendInvest and Habito are fintech lenders, with LendInvest originating bridging loans and buy-to-let, funded through securitizations (LendInvest has completed two public deals so far), retail bonds, funds, and private capital, including a £500m partnership with JP Morgan. Habito mixes technology-enabled mortgage broking with its own buy-to-let originations, funded through Citi’s securitization shelf, and has recently launched the first long-term (up to 40 years) fixed rate mortgage product in the UK, funded through a partnership with CarVal Investors.
  • AstraZeneca, the UK drug company, showed the eager demand for merger and acquisition financings this week when it achieved ultra-tight pricing on a $7bn bond issue to fund its acquisition of US biotech firm Alexion Pharmaceuticals.
  • Kintor Pharmaceutical raised HK$1.17bn ($151m) on Wednesday from a top-up share placement, while a co-founder simultaneously trimmed his stake in the company.